Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 27.5% in December

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 5,000 shares, a drop of 27.5% from the November 30th total of 6,900 shares. Based on an average daily trading volume, of 8,100 shares, the short-interest ratio is presently 0.6 days.

Clinuvel Pharmaceuticals Stock Performance

OTCMKTS:CLVLY traded down $0.14 during mid-day trading on Monday, reaching $7.68. The stock had a trading volume of 852 shares, compared to its average volume of 2,843. Clinuvel Pharmaceuticals has a one year low of $7.46 and a one year high of $11.40. The firm has a 50 day moving average price of $8.58 and a two-hundred day moving average price of $9.36.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).